Advance in thrombopoietic drugs used in treatment of children's immune thrombocytopenia.
- Author:
Jing-Yao MA
1
;
Run-Hui WU
Author Information
1. Department of Hematology, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
- Publication Type:Journal Article
- MeSH:
Child;
Clinical Trials, Phase III as Topic;
Humans;
Thrombocytopenia;
drug therapy;
etiology;
Thrombocytopenia, Neonatal Alloimmune;
drug therapy;
Thrombopoietin;
therapeutic use
- From:
Journal of Experimental Hematology
2012;20(6):1513-1517
- CountryChina
- Language:Chinese
-
Abstract:
Immune thrombocytopenia (ITP) is a common acquired hemorrhagic disease. Conventional view considered its pathogenesis as the destruction of platelets induced by platelet associated antibodies, the target of treatment are inhibiting the production of antibodies and blocking the destruction of platelets in reticuloendothelial system, but they are ineffective in part of ITP patients, who transform to chronic/refractory ITP (C/RITP). As to children's C/RITP, the effect of first-line therapy is low, while the second-line therapy isn't effective definitely and has obvious side effects. The safe and effective second-line drugs to prevent disease progressing are urgently required. Recently, a pathogenesis that decrease the platelet production has been confirmed, thrombopoietic drugs, including thrombopoietin (TPO) and its receptor agonist (TRA), are under research and clinical application gradually. Recombinate human TPO (rhTPO) has accomplished Phase III clinical trails in adult C/RITP and tumor children. The Phase III clinical trails of romiplostim and eltrombopag, as the representative of TRA, in adult C/RITP have been performed. There are also two clinical trails of TRA for children's C/RITP, the efficacy and safety have been approved, with the convenience for using. In pediatric population, they have a good clinical application. In this article the research and development of thrombopoietic drugs and their perspective in pediatric clinical use are reviewed.
